NCT00408083

Crossover Study With MultiHance vs a Comparator for Peripheral MRA

A Phase IIIB, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.1 Mmol/kg of Multihance With 0.1 Mmol/kg of Magnevist for Contrast-Enhanced Magnetic Resonance Angiography(CE-MRA) of Peripheral Arteries

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Bracco Diagnostics, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double blind crossover study designed to compare two different gadolinium products given at the same dose to patients undergoing MRA assessment of lower legs for the evaluation of peripheral steno-occlusive disease.

Conditions

• Peripheral Vascular Disease

Interventions

Type	Name	Description
DRUG	MultiHance	0.5 mmol/kg as a single dose administration
DRUG	Magnevist	0.5 mmol/kg as a single dose administration

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-11-01
• Completion: 2008-12-01
• First posted: 2006-12-06
• Last updated: 2009-03-27

Locations

1 site across 1 country: Italy